This pioneering initiative, INNO4GBM, is funded by Health~Holland and focuses on developing an advanced local injectable hydrogel containing a combined therapy drug-loaded particles, offering a novel therapeutic approach for post-surgical GB patients, ultimately reducing the risk of relapse.
Glioblastoma is one of the most aggressive and treatment-resistant brain tumors. Despite existing therapeutic strategies, patient survival remains critically low due to tumor recurrence. INNO4GBM foster a proof-of-concept of a biodegradable and biocompatible hydrogel capable of sustained drug release at the resection site. The hydrogel will encapsulate a combination of FDA-approved therapeutic drugs to overcome drug resistance and enhance efficacy.
A Collaborative Effort Between Experts from The North of Netherlands:
This project focuses both on the proof-of-concept formulation and also aims for clinical translation from the early stages of drug development, ensuring that the hydrogel meets medical standards for future in vivo validation and potential human trials. The research work will provide a technological package containing preclinical evidence, physicochemical characterization, and materials assessment, paving the way for commercialization.
The financial support from Health~Holland underscores the importance of public-private partnerships in accelerating breakthrough therapies for life-threatening diseases. By contributing to INNO4GBM with €190.000 for the next 36 months, Health~Holland continues to promote Dutch innovation in biomedical technology and cancer treatment.
With a vision to improve post-surgical survival rates and quality of life for GB patients, this project holds significant potential for transforming neuro-oncology care. If successful, the to be developed local therapy could become a new standard for local chemotherapy, reducing recurrence rates and minimizing systemic toxicity.
For further details please contact:
